Mizuho raised the firm’s price target on Elevance Health to $585 from $575 and keeps a Buy rating on the shares. The analyst increased estimates post the company’s Q1 results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target raised to $600 from $580 at Truist
- Elevance Health price target raised to $575 from $574 at RBC Capital
- Elevance Health price target raised to $600 from $557 at Wells Fargo
- Elevance Health price target raised to $605 from $585 at UBS
- Elevance Health price target raised to $621 from $584 at Barclays
